GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Guardant Health Inc (STU:5GH) » Definitions » EV-to-EBITDA

Guardant Health (STU:5GH) EV-to-EBITDA : -10.53 (As of Dec. 12, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Guardant Health EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Guardant Health's enterprise value is €4,506.9 Mil. Guardant Health's EBITDA for the trailing twelve months (TTM) ended in Sep. 2024 was €-428.1 Mil. Therefore, Guardant Health's EV-to-EBITDA for today is -10.53.

The historical rank and industry rank for Guardant Health's EV-to-EBITDA or its related term are showing as below:

STU:5GH' s EV-to-EBITDA Range Over the Past 10 Years
Min: -138.6   Med: -28.2   Max: -4.42
Current: -10.19

During the past 8 years, the highest EV-to-EBITDA of Guardant Health was -4.42. The lowest was -138.60. And the median was -28.20.

STU:5GH's EV-to-EBITDA is ranked worse than
100% of 114 companies
in the Medical Diagnostics & Research industry
Industry Median: 16.35 vs STU:5GH: -10.19

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-12-12), Guardant Health's stock price is €34.17. Guardant Health's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was €-3.887. Therefore, Guardant Health's PE Ratio (TTM) for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


Guardant Health EV-to-EBITDA Historical Data

The historical data trend for Guardant Health's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Guardant Health EV-to-EBITDA Chart

Guardant Health Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial -121.35 -53.46 -29.53 -5.12 -8.02

Guardant Health Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -9.58 -8.02 -6.59 -8.68 -6.78

Competitive Comparison of Guardant Health's EV-to-EBITDA

For the Diagnostics & Research subindustry, Guardant Health's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Guardant Health's EV-to-EBITDA Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Guardant Health's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Guardant Health's EV-to-EBITDA falls into.



Guardant Health EV-to-EBITDA Calculation

Guardant Health's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=4506.895/-428.1
=-10.53

Guardant Health's current Enterprise Value is €4,506.9 Mil.
Guardant Health's EBITDA for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-428.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Guardant Health  (STU:5GH) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Guardant Health's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=34.17/-3.887
=At Loss

Guardant Health's share price for today is €34.17.
Guardant Health's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-3.887.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


Guardant Health EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Guardant Health's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Guardant Health Business Description

Traded in Other Exchanges
Address
3100 Hanover Street, Palo Alto, CA, USA, 94304
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

Guardant Health Headlines

No Headlines